• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PRETEXT II-III期多灶性肝母细胞瘤:无论化疗后卫星灶是否消失,切除卫星灶的意义

PRETEXT II-III multifocal hepatoblastoma: significance of resection of satellite lesions irrespective of their disappearance after chemotherapy.

作者信息

Qureshi Sajid S, Bhagat Monica, Kembhavi Seema, Vora Tushar, Ramadwar Mukta, Talole Sanjay

机构信息

Division of Pediatric Surgical Oncology, Department of Surgical Oncology, Tata Memorial Centre, Ernest Borges Road, Parel, 400012, Bombay, India,

出版信息

Pediatr Surg Int. 2015 Jun;31(6):573-9. doi: 10.1007/s00383-015-3713-0. Epub 2015 Apr 23.

DOI:10.1007/s00383-015-3713-0
PMID:25904441
Abstract

PURPOSE

To determine the outcomes of resection of satellite lesions in PRE-treatment Tumor EXTension (PRETEXT) II and III multifocal hepatoblastoma irrespective of their disappearance after chemotherapy. To compare the overall outcomes of multifocal and unifocal hepatoblastoma.

METHODS

Fourteen patients with PRETEXT II (n = 7) and III (n = 7) multifocal hepatoblastoma treated between April 2006 and July 2014 were analyzed and their outcomes were compared with PRETEXT II and III unifocal hepatoblastoma treated in the similar period.

RESULTS

Satellite lesion or the affected segments with disappeared satellite lesions were resected in 11 patients. Amongst them, all relapses were distant except one in the liver. In contrast, two of three patients developed liver relapse when the affected segments were not resected. None of the patients receiving intensive chemotherapy based on SIOPEL-3 guidelines developed a relapse. The 3-year event-free and overall survival were 38.6 and 42.9% in multifocal hepatoblastoma and 86.4 and 92.4% in unifocal hepatoblastoma (p = 0.001). Multifocality (p = 0.002) and AFP >10,000 after induction chemotherapy significantly affected event-free survival (p = 0.01).

CONCLUSION

Multifocal hepatoblastoma is associated with poor outcomes as compared to unifocal hepatoblastoma. These preliminary observations of relapse and the role of chemotherapy intensification deserve further study in a multicenter controlled trial setting.

摘要

目的

确定预处理肿瘤扩展(PRETEXT)II期和III期多灶性肝母细胞瘤卫星灶切除的结果,无论其在化疗后是否消失。比较多灶性和单灶性肝母细胞瘤的总体结果。

方法

分析2006年4月至2014年7月期间治疗的14例PRETEXT II期(n = 7)和III期(n = 7)多灶性肝母细胞瘤患者,并将其结果与同期治疗的PRETEXT II期和III期单灶性肝母细胞瘤进行比较。

结果

11例患者切除了卫星灶或卫星灶消失的受累节段。其中,除1例肝内复发外,所有复发均为远处复发。相比之下,3例未切除受累节段的患者中有2例发生肝复发。根据SIOPEL-3指南接受强化化疗的患者均未复发。多灶性肝母细胞瘤的3年无事件生存率和总生存率分别为38.6%和42.9%,单灶性肝母细胞瘤为86.4%和92.4%(p = 0.001)。多灶性(p = 0.002)和诱导化疗后甲胎蛋白>10,000显著影响无事件生存率(p = 0.01)。

结论

与单灶性肝母细胞瘤相比,多灶性肝母细胞瘤的预后较差。这些关于复发的初步观察结果以及强化化疗的作用值得在多中心对照试验中进一步研究。

相似文献

1
PRETEXT II-III multifocal hepatoblastoma: significance of resection of satellite lesions irrespective of their disappearance after chemotherapy.PRETEXT II-III期多灶性肝母细胞瘤:无论化疗后卫星灶是否消失,切除卫星灶的意义
Pediatr Surg Int. 2015 Jun;31(6):573-9. doi: 10.1007/s00383-015-3713-0. Epub 2015 Apr 23.
2
[Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].[高风险和标准风险肝母细胞瘤的差异化治疗方案——德国肝脏肿瘤研究HB99的中期报告]
Klin Padiatr. 2003 May-Jun;215(3):159-65. doi: 10.1055/s-2003-39375.
3
Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study.成功治疗儿童高危肝母细胞瘤的剂量密集型多药化疗和手术:SIOPEL-3HR 研究的最终结果。
J Clin Oncol. 2010 May 20;28(15):2584-90. doi: 10.1200/JCO.2009.22.4857. Epub 2010 Apr 20.
4
Improved survival outcome for hepatoblastoma based on an optimal chemotherapeutic regimen--a report from the study group for pediatric solid malignant tumors in the Kyushu area.基于最佳化疗方案的肝母细胞瘤生存结局改善——来自九州地区小儿实体恶性肿瘤研究组的报告
J Pediatr Surg. 2004 Feb;39(2):195-8; discussion 195-8. doi: 10.1016/j.jpedsurg.2003.10.012.
5
Features predicting unresectability in hepatoblastoma.肝母细胞瘤中预测不可切除性的特征。
Cancer. 2007 Sep 1;110(5):1050-8. doi: 10.1002/cncr.22876.
6
Surgical Resection for Hepatoblastoma-Updated Survival Outcomes.肝母细胞瘤的手术切除——更新后的生存结果
J Gastrointest Cancer. 2018 Dec;49(4):493-496. doi: 10.1007/s12029-017-0005-z.
7
Hepatoblastoma--evolution of management and outcome and significance of histology of the resected tumor. A 31-year experience with 40 cases.肝母细胞瘤——治疗方法的演变、预后及切除肿瘤组织学的意义。40例患者的31年经验。
J Pediatr Surg. 2004 Sep;39(9):1321-7. doi: 10.1016/j.jpedsurg.2004.05.020.
8
Resectability and tumor response after preoperative chemotherapy in hepatoblastoma treated by the Japanese Study Group for Pediatric Liver Tumor (JPLT)-2 protocol.日本小儿肝脏肿瘤研究组(JPLT)-2方案治疗的肝母细胞瘤术前化疗后的可切除性及肿瘤反应
J Pediatr Surg. 2016 Dec;51(12):2053-2057. doi: 10.1016/j.jpedsurg.2016.09.038. Epub 2016 Sep 17.
9
Cure of multifocal panhepatic hepatoblastoma: is liver transplantation always necessary?多灶性肝母细胞瘤的治愈:肝移植是否总是必要?
J Pediatr Surg. 2010 May;45(5):1030-6. doi: 10.1016/j.jpedsurg.2010.01.038.
10
Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT.采用日本小儿肝脏肿瘤研究组(JPLT)方案-2治疗的肝母细胞瘤的治疗结果:来自JPLT的报告
Pediatr Surg Int. 2011 Jan;27(1):1-8. doi: 10.1007/s00383-010-2708-0.

引用本文的文献

1
Comparison of Cisplatin Monotherapy and PLADO in the Management in Children with Standard-Risk Hepatoblastoma in a Resource-Challenged Nation.在资源匮乏国家中,顺铂单药治疗与PLADO用于低危儿童肝母细胞瘤管理的比较。
J Indian Assoc Pediatr Surg. 2022 May-Jun;27(3):317-322. doi: 10.4103/jiaps.JIAPS_46_21. Epub 2022 May 12.
2
Benign liver tumors in children: outcomes after resection.儿童良性肝脏肿瘤:切除术后的结局
Pediatr Surg Int. 2015 Dec;31(12):1145-9. doi: 10.1007/s00383-015-3763-3. Epub 2015 Aug 12.

本文引用的文献

1
Predictors of survival after resection of children with hepatoblastoma: A single Asian center experience.肝母细胞瘤患儿切除术后生存的预测因素:一个亚洲单一中心的经验
Eur J Surg Oncol. 2014 Nov;40(11):1533-9. doi: 10.1016/j.ejso.2014.07.033. Epub 2014 Jul 24.
2
Is multifocality a prognostic factor in childhood hepatoblastoma?多灶性是儿童肝母细胞瘤的一个预后因素吗?
Pediatr Blood Cancer. 2014 Sep;61(9):1593-7. doi: 10.1002/pbc.25077. Epub 2014 Apr 23.
3
Relapses in hepatoblastoma patients: clinical characteristics and outcome--experience of the International Childhood Liver Tumour Strategy Group (SIOPEL).
肝母细胞瘤患者的复发:临床特征和结局——国际儿童肝脏肿瘤策略组(SIOPEL)的经验。
Eur J Cancer. 2013 Mar;49(4):915-22. doi: 10.1016/j.ejca.2012.10.003. Epub 2012 Nov 9.
4
Changing treatment and outcome of children with hepatoblastoma: analysis of a single center experience over the last 20 years.改变儿童肝母细胞瘤的治疗方法和结局:对过去 20 年单中心经验的分析。
J Pediatr Surg. 2012 Jul;47(7):1331-9. doi: 10.1016/j.jpedsurg.2011.11.073.
5
Prognostic stratification for children with hepatoblastoma: the SIOPEL experience.肝母细胞瘤患儿的预后分层:SIOPEL 经验。
Eur J Cancer. 2012 Jul;48(10):1543-9. doi: 10.1016/j.ejca.2011.12.011. Epub 2012 Jan 13.
6
Successful nontransplant resection of POST-TEXT III and IV hepatoblastoma.成功切除 POST-TEXT Ⅲ期和Ⅳ期肝母细胞瘤。
Cancer. 2011 May 1;117(9):1976-83. doi: 10.1002/cncr.25722. Epub 2010 Nov 16.
7
Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT.采用日本小儿肝脏肿瘤研究组(JPLT)方案-2治疗的肝母细胞瘤的治疗结果:来自JPLT的报告
Pediatr Surg Int. 2011 Jan;27(1):1-8. doi: 10.1007/s00383-010-2708-0.
8
Cure of multifocal panhepatic hepatoblastoma: is liver transplantation always necessary?多灶性肝母细胞瘤的治愈:肝移植是否总是必要?
J Pediatr Surg. 2010 May;45(5):1030-6. doi: 10.1016/j.jpedsurg.2010.01.038.
9
Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study.成功治疗儿童高危肝母细胞瘤的剂量密集型多药化疗和手术:SIOPEL-3HR 研究的最终结果。
J Clin Oncol. 2010 May 20;28(15):2584-90. doi: 10.1200/JCO.2009.22.4857. Epub 2010 Apr 20.
10
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma.顺铂与顺铂加阿霉素治疗标准风险肝母细胞瘤的比较。
N Engl J Med. 2009 Oct 22;361(17):1662-70. doi: 10.1056/NEJMoa0810613.